GIP Receptor Antagonism Eliminates Paradoxical Growth Hormone Secretion in Some Patients With Acromegaly

Context: About 30% of patients with active acromegaly experience paradoxically increased growth hormone (GH) secretion during the diagnostic oral glucose tolerance test (OGTT). Endogenous glucose-dependent insulinotropic polypeptide (GIP) is implicated in this paradoxical secretion.

Objective: We used the GIP receptor (GIPR) antagonist GIP(3-30)NH2 to test the hypothesis that GIP mediates this paradoxical response when GIPR is abundantly expressed in somatotropinomas.

Methods: A total of 25 treatment-naive patients with acromegaly were enrolled. Each patient underwent one OGTT during simultaneous placebo infusion and one OGTT during a GIP(3-30)NH2 infusion. Blood samples were drawn at baseline and regularly after infusions to measure GH. We assessed pituitary adenoma size by magnetic resonance imaging and GIPR expression by immunohistochemistry on resected somatotropinomas. For mechanistic confirmation, we applied in vitro and ex vivo approaches. The main outcome measure was the effect of GIP(3-30)NH2 on paradoxical GH secretion during OGTT as a measure of GIP involvement.

Results: In 4 of 7 patients with paradoxical GH secretion, GIP(3-30)NH2 infusion completely abolished the paradoxical response (P = .0003). Somatotrophs were available from 3 of 4 of these patients, all showing abundant GIPR expression. Adenoma size did not differ between patients with and without paradoxical GH secretion.

Conclusion: Of 25 patients with acromegaly, 7 had paradoxical GH secretion during OGTT, and pharmaceutical GIPR blockade abolished this secretion in 4. Corresponding somatotroph adenomas abundantly expressed GIPR, suggesting a therapeutic target in this subpopulation of patients. In vitro and ex vivo analyses confirmed the role of GIP and the effects of the antagonist.

References

Stensen S, Gasbjerg L, Krogh L, Skov-Jeppesen K, Sparre-Ulrich A, Jensen M . Effects of endogenous GIP in patients with type 2 diabetes. Eur J Endocrinol. 2021; 185(1):33-45. DOI: 10.1530/EJE-21-0135. View

Holdaway I, Rajasoorya R, Gamble G . Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004; 89(2):667-74. DOI: 10.1210/jc.2003-031199. View

Sonne D, Rehfeld J, Holst J, Vilsboll T, Knop F . Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1. Eur J Endocrinol. 2014; 171(4):407-19. DOI: 10.1530/EJE-14-0309. View

Zahr R, Fleseriu M . Updates in Diagnosis and Treatment of Acromegaly. Eur Endocrinol. 2018; 14(2):57-61. PMC: 6182922. DOI: 10.17925/EE.2018.14.2.57. View

Melmed S, Casanueva F, Klibanski A, Bronstein M, Chanson P, Lamberts S . A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2012; 16(3):294-302. PMC: 3730092. DOI: 10.1007/s11102-012-0420-x. View

Arnardottir S, Jaras J, Burman P, Berinder K, Dahlqvist P, Erfurth E . Long-term outcomes of patients with acromegaly: a report from the Swedish Pituitary Register. Eur J Endocrinol. 2022; 186(3):329-339. DOI: 10.1530/EJE-21-0729. View

Asmar M, Asmar A, Simonsen L, Gasbjerg L, Sparre-Ulrich A, Rosenkilde M . The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor. Diabetes. 2017; 66(9):2363-2371. DOI: 10.2337/db17-0480. View

Regazzo D, Losa M, Albiger N, Terreni M, Vazza G, Ceccato F . The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of somatotropinomas. Eur J Endocrinol. 2017; 176(5):543-553. DOI: 10.1530/EJE-16-0831. View

Ceccato F, Vedolin C, Voltan G, Antonelli G, Barbot M, Basso D . Paradoxical GH increase after oral glucose load in subjects with and without acromegaly. J Endocrinol Invest. 2023; 47(1):213-221. PMC: 10776735. DOI: 10.1007/s40618-023-02138-9. View

10.

Duger H, Bostan H, Deryol H, NasiroglU Imga N, Ucan B, Calapkulu M . Paradoxical GH increase during oral glucose load may predict overall remission in acromegalic patients. Growth Horm IGF Res. 2022; 67:101501. DOI: 10.1016/j.ghir.2022.101501. View

11.

Gabe M, Sparre-Ulrich A, Pedersen M, Gasbjerg L, Inoue A, Brauner-Osborne H . Human GIP(3-30)NH inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors. Biochem Pharmacol. 2018; 150:97-107. DOI: 10.1016/j.bcp.2018.01.040. View

12.

Stensen S, Gasbjerg L, Rosenkilde M, Vilsboll T, Holst J, Hartmann B . Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in β-Cell Function in Patients With Type 2 Diabetes. Diabetes. 2022; 71(10):2209-2221. DOI: 10.2337/db22-0059. View

13.

Lindgren O, Carr R, Deacon C, Holst J, Pacini G, Mari A . Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab. 2011; 96(8):2519-24. DOI: 10.1210/jc.2011-0266. View

14.

Hansen L, Sparre-Ulrich A, Christensen M, Knop F, Hartmann B, Holst J . N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor. Br J Pharmacol. 2015; 173(5):826-38. PMC: 4761099. DOI: 10.1111/bph.13384. View

15.

Gasbjerg L, Helsted M, Hartmann B, Sparre-Ulrich A, Veedfald S, Stensen S . GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. J Clin Endocrinol Metab. 2020; 105(3). DOI: 10.1210/clinem/dgz175. View

16.

Colao A, Merola B, Ferone D, Calabrese M, Longobardi S, Spaziante R . Effect of corticotrophin-releasing hormone administration on growth hormone levels in acromegaly: in vivo and in vitro studies. Eur J Endocrinol. 1994; 131(1):14-9. DOI: 10.1530/eje.0.1310014. View

17.

Melmed S, Bronstein M, Chanson P, Klibanski A, Casanueva F, Wass J . A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018; 14(9):552-561. PMC: 7136157. DOI: 10.1038/s41574-018-0058-5. View

18.

Skov-Jeppesen K, Svane M, Martinussen C, Gabe M, Gasbjerg L, Veedfald S . GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men. Bone. 2019; 125:178-185. DOI: 10.1016/j.bone.2019.05.014. View

19.

Fleseriu M, Langlois F, Lim D, Varlamov E, Melmed S . Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022; 10(11):804-826. DOI: 10.1016/S2213-8587(22)00244-3. View

20.

Hage M, Janot C, Salenave S, Chanson P, Kamenicky P . MANAGEMENT OF ENDOCRINE DISEASE: Etiology and outcome of acromegaly in patients with a paradoxical GH response to glucose. Eur J Endocrinol. 2021; 184(6):R261-R268. DOI: 10.1530/EJE-20-1448. View